Forte Biosciences, Inc.
FBRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeForte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. At a $1.63B market cap, Forte Biosciences, Inc. ranks as a small-cap company within healthcare. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes.
Market Cap
$1.63B
Beta
2.65
P/E (TTM)
—
P/E (Fwd)
-19.52
EPS (TTM)
$-4.57
EPS (Fwd)
$-3.94
ROE
-62.3%
ROA
-37.8%
Cash
$198.5M
Total Debt
$0
Free CF
-$41.3M
52W Change
599.9%
Annual Financials
Cash vs Debt
Where FBRX stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, FBRX finished 115.72% above its 150-day moving average ($35.69) and 136.60% above its 200-day moving average ($32.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FBRX overbought or oversold?
At the August 28, 2026 close, FBRX's RSI(14) was 70.8, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Forte Biosciences, Inc. reports $198.5M in cash and $0 in total debt. Free cash flow is running at -$41.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -62.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Forte Biosciences, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing FBRX.